A Phase II Study of Weekly Dose-Dense Nanoparticle Paclitaxel (ABI-007), Carboplatin TM With Herceptin R As First-Line Therapy of Advanced Her-2 Positive Breast Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Percentage of patients who achieve an objective confirmed complete or partial target lesion response based on the RECIST response criteria.
16 weeks
Yes
Andrew Seidman, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
CA016
NCT00093145
June 2004
October 2008
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
Rhode Island Hospital | Providence, Rhode Island 02903 |
Southwest Regional Cancer Center | Austin, Texas 78705 |
Maine Center for Cancer Medicine and Blood Disorders | Scarborough, Maine 04074 |
Palm Beach Cancer Institute | West Palm Beach, Florida 33401 |
Washington Hospital Center | Washington, District of Columbia 20010 |
Florida Cancer Institute | New Port Richey, Florida 34652 |
Breastlink Med Group | Long Beach, California 90806 |
Hematology/Oncology P.C. Carl & Dorothy Bennet Cancer Center | Stamford, Connecticut 06902 |
Lombardi Cancer Center Georgetown University Hospital | Washington, District of Columbia 2007 |
Gulf Coast Oncology Associates | St. Petersburg, Florida 33705 |
Gerogia Cancer Specialist | Atlanta, Georgia 30341 |
University of Pittsburgh Medical Center Magee Womens Hospital | Pittsburgh, Pennsylvania 15213 |
Swedish Medical Center Cancer Institute Research | Seattle, Washington 98104 |